# Study of ABT-700 in Subjects With Advanced Solid Tumors

> **NCT01472016** · PHASE1 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 74 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ABT-700
- **DRUG:** docetaxel
- **DRUG:** FOLFIRI
- **DRUG:** cetuximab
- **DRUG:** erlotinib
- **DRUG:** ABT-700

## Key facts

- **NCT ID:** NCT01472016
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-06
- **Primary completion:** 2017-04-27
- **Final completion:** 2017-04-27
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2017-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01472016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01472016, "Study of ABT-700 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01472016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*